Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Author: search.filters.author.Tufan, Ali EvrenSubject: search.filters.subject.quality of life

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Is Functional Improvement Always Correlated with Symptomatic Improvement in Children with Attention-Deficit/Hyperactivity Disorder Managed with Oros Methylphenidate? A Prospective Open-Label Naturalistic Follow-Up Study
    (AVES, 2020-01-01) Tarakcioglu, Mahmut Cem; Caliskan, Yasin; Kadak, Muhammed Tayyib; Aliyev, Nilufer Okumus; Aksoy, Umut Mert; Tufan, Ali Evren; Gundogdu, Ozlem Yildiz; Memik, Nursu Cakin; Weiss, Margaret D.
    Background: To investigate the relationship between symptomatic improvement and functional improvement in children with attention deficit hyperactivity disorder (ADHD) who were being treated with OROS methylphenidate. Methods: Parents evaluated the severity of ADHD symptoms on the Turgay-DSM-IV ADHD/Disruptive Behavior Disorders Scale (T-DSM-IV). They assessed functioning on the Weiss Functional Impairment Rating Scale - Parent Form (WFIRS-P), and the Pediatric Quality of Life Inventory (PedsQL) was used to assess quality of life. Clinicians rated global outcome on the Clinical Global Impressions Scale (CGI). Response was measured in terms of the following criteria: a 20\% change in symptoms, a CGI-I score that was much improved (2) or very much improved (1), or an improvement of 0.25 (the minimally important difference) on the WFIRS. Improvement in quality of life was defined as >= 20\% change in PedsQL score. Results: Sixty-three children completed the study. After 12 weeks, 77.7\% of patients met the a priori criteria for treatment response rate. Among patients who exhibited improvement in symptoms, 42.9\% also showed improved functioning. Among those who showed improved functioning, 95.5\% showed improvement in symptoms. Of patients who showed improvement in symptoms, 34.6\% percent also showed improvement in quality of life. Of those who showed improvement in quality of life, 94.4\% also showed improvement in symptoms. Conclusions: Evaluation of changes in functional improvement, quality of life improvement, and symptom improvement during ADHD treatment enables clinicians to identify individuals whose functional impairment/quality of life persists despite symptom improvement. On that basis, additional treatment interventions can be organized for those individuals.
  • No Thumbnail Available
    Item
    Psychiatric comorbidities in cases with Duchenne muscular dystrophy: a case series
    (YERKURE TANITIM \& YAYINCILIK HIZMETLERI A S, 2019-01-01) Ozer, Urun; Tufan, Ali Evren
    Duchenne muscular dystrophy is a hereditary multisystem disease caused by mutations in the dystrophin gene, characterized by proximal muscle weakness in early childhood, generally resulting in death before the age of 20 years. Cognitive and neurobehavioral changes are prevalent in Duchenne muscular dystrophy. Furthermore, psychiatric disorders have been reported. Here we present 12 cases with Duchenne muscular dystrophy, aiming to address psychiatric comorbidities and to examine anxiety and depression levels as well as the quality of life in these cases. Twelve inpatients with Duchenne muscular dystrophy were followed, according to their ages, by an adult psychiatrist or a child and adolescent psychiatrist. Psychiatric examination and detailed psychiatric and medical history-taking were performed. The Hospital Anxiety and Depression Scale (HADS) and the KINDL Questionnaire were administered and family interviews conducted. In 5 cases, comorbid psychiatric diagnoses were present, including depression, obsessive compulsive disorder, and generalized anxiety disorder. Anxiety levels according to the HADS were higher than threshold level in two cases. Alongside cognitive and neurobehavioral changes, psychiatric comorbidities such as depression, obsessive compulsive disorder, or generalized anxiety disorder might be seen in Duchenne muscular dystrophy, as was the case with our patients. At the same time, due to the chronic illness process and disability involved, psychosocial support is needed both for the patient and the family. Therefore, it is important that psychiatry should be part of a holistic treatment approach and that psychiatric support should be provided right from the first years in these cases.